A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Part of paid clinical trials in Grand Rapids, Michigan.

Sponsor
AstraZeneca
Study ID
NCT07115043
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • AZD6750 — DRUG
    AZD6750- CD8 guided IL-2
  • rilvegostomig — DRUG
    Rilvegostomig- PD1-TIGIT bispecific antibody

Study Details

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Key Dates

Start date
Jul 29, 2025
Status verified
Jun 2026
Primary completion
Oct 2, 2029
Completion
Oct 2, 2029

Study Design

Enrollment
60 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Module 1
    AZD6750 administered intravenously (IV) as a single agent
  • Experimental: Module 2
    AZD6750 given in combination with rilvegostomig (IV)

Primary Outcome Measure

Safety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion) [ Time Frame: Measured from the informed consent until Day 90 post-last dose. ]

Central Contacts

Locations (6)

FacilityCityStateZIPSite coordinators
Research SiteGrand RapidsMichigan49546-
Research SiteSt LouisMissouri63110-
Research SitePittsburghPennsylvania15232-
Research SiteHoustonTexas77030-
Research SiteSan AntonioTexas78229-
Research SiteFairfaxVirginia22031-

Find similar trials in Grand Rapids, MI

By condition
Head and neck cancerMelanomaLung cancerKidney cancerBreast cancer
By specialty
OncologyENTSkin cancerDermatologyLung oncologyLung diseaseUrologyBreast oncologyWomen's health
By research site
Research Site· Grand Rapids, MIResearch Site· St Louis, MOResearch Site· Pittsburgh, PAResearch Site· Houston, TXResearch Site· San Antonio, TXResearch Site· Fairfax, VA

Related Studies